Resveratrol and its metabolites elicit neuroprotection via high-affinity binding to the laminin receptor at low nanomolar concentrations.
67-kDa laminin receptor
cAMP
epigallocatechin-3-gallate
glycosaminoglycan
neuroprotection
resveratrol-3-glucuronide
Journal
FEBS letters
ISSN: 1873-3468
Titre abrégé: FEBS Lett
Pays: England
ID NLM: 0155157
Informations de publication
Date de publication:
27 Feb 2024
27 Feb 2024
Historique:
revised:
28
01
2024
received:
07
11
2023
accepted:
30
01
2024
medline:
28
2
2024
pubmed:
28
2
2024
entrez:
27
2
2024
Statut:
aheadofprint
Résumé
Resveratrol prevents various neurodegenerative diseases in animal models despite reaching only low nanomolar concentrations in the brain after oral administration. In this study, based on the quenching of intrinsic tryptophan fluorescence and molecular docking, we found that trans-resveratrol, its conjugates (glucuronide and sulfate), and dihydro-resveratrol (intestinal microbial metabolite) bind with high affinities (K
Identifiants
pubmed: 38413095
doi: 10.1002/1873-3468.14835
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : NINDS R21 NS116720
Pays : United States
Organisme : NIH HHS
ID : NINDS/NIA RF1 NS130681
Pays : United States
Informations de copyright
© 2024 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Baur JA and Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5, 493-506.
Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, Fokou PVT, Martins N and Sharifi-Rad J (2018) Resveratrol: a double-edged sword in health benefits. Biomedicine 6, 91.
Bastianetto S, Ménard C and Quirion R (2015) Neuroprotective action of resveratrol. Biochim Biophys Acta 1852, 1195-1201.
Gruber J, Tang SY and Halliwell B (2007) Evidence for a trade-off between survival and fitness caused by resveratrol treatment of Caenorhabditis elegans. Ann N Y Acad Sci 1100, 530-542.
Singh N, Agrawal M and Doré S (2013) Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models. ACS Chem Nerosci 4, 1151-1162.
Rocha-González HI, Ambriz-Tututi M and Granados-Soto V (2008) Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci Ther 14, 234-247.
Pasinetti GM, Wang J, Ho L, Zhao W and Dubner L (2015) Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. Biochim Biophys Acta 1852, 1202-1208.
Rege SD, Geetha T, Griffin GD, Broderick TL and Babu JR (2014) Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci 6, 218.
Arbo BD, André-Miral C, Nasre-Nasser RG, Schimith LE, Santos MG, Costa-Silva D, Muccillo-Baisch AL and Hort MA (2020) Resveratrol derivatives as potential treatments for Alzheimer's and Parkinson's disease. Front Aging Neurosci 12, 103.
Lopez MS, Dempsey RJ and Vemuganti R (2015) Resveratrol neuroprotection in stroke and traumatic CNS injury. Neurochem Int 89, 75-82.
Zhu H, Huang J, Chen Y, Li X, Wen J, Tian M, Ren J, Zhou L and Yang Q (2022) Resveratrol pretreatment protects neurons from oxygen-glucose deprivation/reoxygenation and ischemic injury through inhibiting ferroptosis. Biosci Biotechnol Biochem 86, 704-716.
Feng X, Liang N, Zhu D, Gao Q, Peng L, Dong H, Yue Q, Liu H, Bao L, Zhang J et al. (2013) Resveratrol inhibits β-amyloid-induced neuronal apoptosis through regulation of SIRT1-ROCK1 signaling pathway. PLoS One 8, e59888.
Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, Szeto HH, Park B and Reddy PH (2010) Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 20, S609-S631.
Raval AP, Dave KR and Perez-Pinzon MA (2006) Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab 26, 1141-1147.
Walle T (2011) Bioavailability of resveratrol. Ann N Y Acad Sci 1215, 9-15.
Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP, Fogliano V and Marchelli R (2005) Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 49, 495-504.
Walle T, Hsieh F, DeLegge MH, Oatis JE Jr and Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32, 1377-1382.
Sergides C, Chirilă M, Silvestro L, Pitta D and Pittas A (2016) Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. Exp Ther Med 11, 164-170.
Poór M, Kaci H, Bodnárová S, Mohos V, Fliszár-Nyúl E, Kunsági-Máté S, Özvegy-Laczka C and Lemli B (2022) Interactions of resveratrol and its metabolites (resveratrol-3-sulfate, resveratrol-3-glucuronide, and dihydroresveratrol) with serum albumin, cytochrome P450 enzymes, and OATP transporters. Biomed Pharmacother 151, 113136.
Burkon A and Somoza V (2008) Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 52, 549-557.
Lu DL, Ding DJ, Yan WJ, Li RR, Dai F, Wang Q, Yu SS, Li Y, Jin XL and Zhou B (2013) Influence of glucuronidation and reduction modifications of resveratrol on its biological activities. Chembiochem 14, 1094-1104.
Patel KR, Andreadi C, Britton RG, Horner-Glister E, Karmokar A, Sale S, Brown VA, Brenner DE, Singh R, Steward WP et al. (2013) Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med 5, 205ra133.
Lasa A, Churruca I, Eseberri I, Andrés-Lacueva C and Portillo MP (2012) Delipidating effect of resveratrol metabolites in 3T3-L1 adipocytes. Mol Nutr Food Res 56, 1559-1568.
Juan ME, Maijó M and Planas JM (2010) Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal 51, 391-398.
Menet MC, Baron S, Taghi M, Diestra R, Dargère D, Laprévote O, Nivet-Antoine V, Beaudeux JL, Bédarida T and Cottart CH (2017) Distribution of trans-resveratrol and its metabolites after acute or sustained administration in mouse heart, brain, and liver. Mol Nutr Food Res 61, doi: 10.1002/mnfr.201600686
Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM and Zhang Z (2004) Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 43, 11417-11426.
Gomes BAQ, Silva JPB, Romeiro CFR, dos Santos SM, Rodrigues CA, Gonçalves PR, Sakai JT, Mendes PFS, Varela ELP and Monteiro MC (2018) Neuroprotective mechanisms of resveratrol in Alzheimer's disease: role of SIRT1. Oxid Med Cell Longev 2018, 8152373.
DiGiacomo V and Meruelo D (2016) Looking into laminin receptor: critical discussion regarding the non-integrin 37/67-kDa laminin receptor/RPSA protein. Biol Rev Camb Philos Soc 91, 288-310.
Pesapane A, Ragno P, Selleri C and Montuori N (2017) Recent advances in the function of the 67 kDa laminin receptor and its targeting for personalized therapy in cancer. Curr Pharm Des 23, 4745-4757.
Rao CN, Castronovo V, Schmitt MC, Wewer UM, Claysmith AP, Liotta LA and Sobel ME (1989) Evidence for a precursor of the high-affinity metastasis-associated murine laminin receptor. Biochemistry 28, 7476-7486.
Tachibana H, Koga K, Fujimura Y and Yamada K (2004) A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol 11, 380-381.
Gopalakrishna R, Oh A, Hou L, Lee E, Aguilar J, Li A and Mack WJ (2023) Flavonoid quercetin and its glucuronide and sulfate conjugates bind to 67-kDa laminin receptor and prevent neuronal cell death induced by serum starvation. Biochem Biophys Res Commun 671, 116-123.
Hayashi D, Mouchlis VD, Okamoto S, Namba T, Wang L, Li S, Ueda S, Yamanoue M, Tachibana H, Arai H et al. (2022) Vitamin E functions by association with a novel binding site on the 67 kDa laminin receptor activating diacylglycerol kinase. J Nutr Biochem 110, 109129.
Yammine A, Gao J and Kwan AH (2019) Tryptophan fluorescence quenching assays for measuring protein-ligand binding affinities: principles and a practical guide. Bio Protoc 9, e3253.
Trott O and Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31, 455-461.
Gopalakrishna R, Gundimeda U, Zhou S, Bui H, Davis A, McNeill T and Mack W (2018) Laminin-1 induces endocytosis of 67KDa laminin receptor and protects Neuroscreen-1 cells against death induced by serum withdrawal. Biochem Biophys Res Commun 495, 230-237.
Fujimura Y, Sumida M, Sugihara K, Tsukamoto S, Yamada K and Tachibana H (2012) Green tea polyphenol EGCG sensing motif on the 67-kDa laminin receptor. PLoS ONE 7, e37942.
Gundimeda U, McNeill TH, Elhiani AA, Schiffman JE, Hinton DR and Gopalakrishna R (2012) Green tea polyphenols precondition against cell death induced by oxygen-glucose deprivation via stimulation of laminin receptor, generation of reactive oxygen species, and activation of protein kinase Cepsilon. J Biol Chem 287, 34694-34708.
Ould-Abeih MB, Petit-Topin I, Zidane N, Baron B and Bedouelle H (2012) Multiple folding states and disorder of ribosomal protein SA, a membrane receptor for laminin, anticarcinogens, and pathogens. Biochemistry 51, 4807-4821.
Pesapane A, Di Giovanni C, Rossi FW, Alfano D, Formisano L, Ragno P, Selleri C, Montuori N and Lavecchia A (2015) Discovery of new small molecules inhibiting 67 kDa laminin receptor interaction with laminin and cancer cell invasion. Oncotarget 6, 18116-18133.
Brittes J, Lúcio M, Nunes C, Lima JL and Reis S (2010) Effects of resveratrol on membrane biophysical properties: relevance for its pharmacological effects. Chem Phys Lipids 163, 747-754.
Costa R, Costa Lima SA, Gameiro P and Reis S (2021) On the development of a cutaneous flavonoid delivery system: advances and limitations. Antioxidants (Basel) 10, 1376.
Ardini E, Pesole G, Tagliabue E, Magnifico A, Castronovo V, Sobel ME, Colnaghi MI and Ménard S (1998) The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution. Mol Biol Evol 15, 1017-1025.
Yang G, Ge S, Singh R, Basu S, Shatzer K, Zen M, Liu J, Tu Y, Zhang C, Wei J et al. (2017) Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metab Rev 49, 105-138.
Klimas R and Mikus G (2014) Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. Br J Anaesth 113, 935-944.
Hundt C, Peyrin JM, Haïk S, Gauczynski S, Leucht C, Rieger R, Riley ML, Deslys JP, Dormont D, Lasmézas CI et al. (2001) Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J 20, 5876-5886.
Cardin AD and Weintraub HJ (1989) Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9, 21-32.
Crijns H, Adyns L, Ganseman E, Cambier S, Vandekerckhove E, Pörtner N, Vanbrabant L, Struyf S, Gerlza T, Kungl A et al. (2022) Affinity and specificity for binding to glycosaminoglycans can be tuned by adapting peptide length and sequence. Int J Mol Sci 23, 447.
Han YS, Bastianetto S, Dumont Y and Quirion R (2006) Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J Pharmacol Exp Ther 318, 238-245.
Gopalakrishna R, Lin CY, Oh A, Le C, Yang S, Hicks A, Kindy MS, Mack WJ and Bhat NR (2022) cAMP-induced decrease in cell-surface laminin receptor and cellular prion protein attenuates amyloid-β uptake and amyloid-β-induced neuronal cell death. FEBS Lett 596, 2914-2927.
Sakamoto K, Karelina K and Obrietan K (2011) CREB: a multifaceted regulator of neuronal plasticity and protection. J Neurochem 116, 1-9.
Gündüz D, Troidl C, Tanislav C, Rohrbach S, Hamm C and Aslam M (2019) Role of PI3K/Akt and MEK/ERK signalling in cAMP/Epac-mediated endothelial barrier stabilisation. Front Physiol 10, 1387.
Murray AJ and Shewan DA (2008) Epac mediates cyclic AMP-dependent axon growth, guidance and regeneration. Mol Cell Neurosci 38, 578-588.